Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions

Keyphrases

• Advanced Stage 100%
• Squamous Cell Lung Cancer 100%
• Immune Checkpoint Inhibitors 100%
• Chemotherapy 50%
• CTLA-4 Inhibitors 50%
• Anti-programmed Cell Death Protein 1 (anti-PD-1) 50%
• Non-small Cell Lung Cancer (NSCLC) 25%
• Lung Adenocarcinoma 25%
• Novel Therapeutics 25%
• Patient Outcomes 25%
• Monotherapy 25%
• Prognostic Biomarker 25%
• Translational Research 25%
• Immunotherapeutic Approaches 25%
• Histological Subtypes 25%
• Treatment Paradigms 25%
• Programmed Death-ligand 1 (PD-L1) 25%
• Molecular Biology 25%
• Artificial Intelligence 25%
• First-line Regimen 25%
• Multi-omics 25%
• Without Chemotherapy 25%
• Omics Techniques 25%
• Bispecific Antibody 25%
• Beyond PD 25%
• Precision Oncology 25%
• Durable Clinical Benefit 25%
• Personalized Cancer Vaccine 25%
• Optimal Regimen 25%
• Robust Biomarkers 25%
• Clinical Trials Research 25%
• Novel Immune Checkpoints 25%

Immunology and Microbiology

• Immunotherapy 100%
• Squamous Cell 100%
• Immune Checkpoint Inhibitor 100%
• Lung 100%
• Cytotoxic T Lymphocyte Antigen 4 Antibody 50%
• Programmed Death-Ligand 1 25%
• Multi-Omics 25%
• Bispecific Antibody 25%
• Tumor Vaccine 25%
• Artificial Intelligence 25%

Biochemistry, Genetics and Molecular Biology

• Immune Checkpoint Inhibitor 100%
• Clinical Trial 25%
• Molecular Biology 25%
• PD-L1 25%
• Artificial Intelligence 25%
• Multi-Omics 25%